Already registered? Need to register? Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts

PCSK9 inhibition at the limits

PCSK9 inhibition at the limits

With the PCSK9 inhibitors, are we now at the limit for LDL-C lowering? And if so, which patients are the priorities for this novel therapy in clinical practice? PCSK9 Forum Co-Editor Professor John Chapman discusses these important questions in this video. Pause 100/100 Production and…

read more »
PCSK9 Inhibitors for Treatment of High Cholesterol levels: Effectiveness and Value

PCSK9 Inhibitors for Treatment of High Cholesterol levels: Effectiveness and Value

Ciaran Kohli-Lynch, working with Professor Andrew Briggs, University of Glasgow, UK critically appraises the findings and implications of the Institute for Clinical and Economic Review (ICER) report regarding the value of PCSK9 inhibitors in high cardiovascular risk patients. A summary of the report was published as:…

read more »
Lipoprotein-associated PCSK9: Physiological implications?

Lipoprotein-associated PCSK9: Physiological implications?

Professor Sergio Fazio, The Knight Cardiovascular Institute of OHSU, Portland, USA overviews the physiological implications of lipoprotein-associated PCSK9.  Studies show that only 40% of total plasma PCSK9 associates with LDL. This raises a key question: Does lipoprotein-bound PCSK9 more accurately reflect PCSK9 activity?

read more »
Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?

Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?

Professor Packard, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK discusses follow-up data from major statin trials and considers the potential mechanism for the legacy effect seen in some trials, such as WOSCOPS. These findings raise a key question: Would phased…

read more »
A view from North America

A view from North America

Professor Henry Ginsberg , Columbia University, New York, USA

read more »
PCSK9 monoclonal antibody therapy: pharmacodynamics, efficacy and safety

PCSK9 monoclonal antibody therapy: pharmacodynamics, efficacy and safety

Webcast Prof Evan Stein, University of Cincinnati Medical Center, Cincinnati, Ohio, USA overviews the clinical development of PCSK9 monoclonal antibody therapy Report from State-of-the-Art PCSK9 Science: Current understanding and therapeutic perspectives Prof Evan Stein discusses the pharmacodynamics of the two most advanced PCSK9 monoclonal antibody…

read more »
Mechanistic insights from PCSK9 LOF mutations

Mechanistic insights from PCSK9 LOF mutations

Mechanistic insights from PCSK9 LOF mutations with a particular focus on data from the Copenhagen studies, were discussed by Professor Anne Tybjaerg-Hansen, Rigshospitalet, Copenhagen University Hospital, and University of Copenhagen, Denmark. Seminal studies showed that carriage of LOF mutations was associated reduction in LDL cholesterol…

read more »
How can we optimise PCSK9-targeted therapies?

How can we optimise PCSK9-targeted therapies?

Highly relevant to these discussions was how to optimise the use of PCSK9-targeted therapies, discussed from both European (Professor Luís Masana, University Rovira and Virgili, Reus-Tarragona, Spain) and North American (Professor Henry Ginsberg, Columbia University, New York, USA) perspectives, from the guidelines perspectives. There are…

read more »
Evidence for the effects of PCSK9 beyond the liver

Evidence for the effects of PCSK9 beyond the liver

Evidence for the effects of PCSK9 beyond the liver was discussed by Professor Bertrand Cariou, INSERM UMR1087, l’Institut du Thorax, Nantes, France. A seminal paper showed that PCSK9 exerts hypocholesterolaemic effects via action in both the liver and intestine; in the latter case, PCSK9 modulates…

read more »